ºÚÁÏÍø

Quantum-Si Incorporated, a life sciences company, announces its inclusion in the Russell 2000® Index effective June 27, 2022. This significant milestone follows its public trading anniversary and is expected to enhance stock visibility among investors. The Russell indexes serve as benchmarks for numerous investment strategies, managing about $12 trillion in assets. The company is advancing its single molecule protein sequencing technology, aiming to transform proteomics and improve drug discovery.

Quantum-Si Incorporated (NASDAQ: QSI) announced the appointment of Vikram Bajaj, Ph.D., to its Board of Directors on June 16, 2022. Dr. Bajaj, co-founder and former Chief Scientific Officer of Verily, brings extensive expertise in precision medicine and life sciences investment. His role is expected to bolster Quantum-Si's commercialization strategy for its next-generation protein sequencing system, which aims to revolutionize proteomics. CEO Jonathan Rothberg highlighted Bajaj's significant experience as critical to advancing the company's ambitious goals.

Quantum-Si (NASDAQ: QSI) presented significant advancements in its protein sequencing technology at the Next-Generation Protein Analysis Conference. Dr. Brian Reed announced the ability to cover over 70% of the human proteome and identify up to 90% of proteins, including vital post-translational modifications. The company's Platinumâ„¢ Protein Sequencing Platform is on track for commercialization later this year, enhancing research capabilities across various medical fields like oncology and cardiology. For more information, visit Quantum-Si's website.

Quantum-Si Incorporated (Nasdaq: QSI) announced its participation in the 2022 Jefferies Healthcare Conference from June 8-10 in New York, NY. The company's management will present on June 10 at 8:30 am ET. A live and archived webcast of the event will be accessible in the Investors section of Quantum-Si's website. Quantum-Si is pioneering single molecule protein sequencing technology to advance drug discovery and diagnostics, utilizing a unique semiconductor chip for enhanced proteomic research.

Quantum-Si Incorporated (Nasdaq: QSI) announced its participation in the Next-Generation Protein Analysis and Detection Conference in Ghent, Belgium, on May 30-31, 2022. Dr. Brian Reed, Head of Research, will present on May 31 at 2:40 PM CEST, discussing advancements in real-time dynamic single-molecule protein sequencing. The conference aims to highlight innovations in proteomics, a field Quantum-Si is transforming with its novel semiconductor chip technology. The presentation's abstract will be available until August 30, 2022, for registered attendees.

Quantum-Si Incorporated (NASDAQ: QSI) is set to present at the 2022 UBS Global Healthcare Conference from May 23-25, 2022, at the Lotte New York Palace. The presentation is scheduled for May 23, 2022, at 3:30 pm ET. Quantum-Si specializes in single molecule protein sequencing and is advancing the field of proteomics with innovative semiconductor technology. The event will be accessible via a live and archived webcast on the Quantum-Si Investors website.

Quantum-Si (Nasdaq: QSI) announced its first-quarter financial results for 2022, reporting a net loss of $35.2 million, up from $11.8 million in Q1 2021. Research and development expenses increased significantly to $18.8 million, driven by higher personnel costs. The company held $434.8 million in cash and marketable securities, ensuring adequate funding for future initiatives. Quantum-Si also made progress in technology transfer and announced the appointment of Patrick Schneider as President & COO, aiming for a launch in the second half of 2022.

Quantum-Si Incorporated (NASDAQ: QSI) appointed Patrick Schneider, Ph.D., as President and COO, succeeding Michael McKenna, who will stay on as Executive VP of Product Development. Schneider brings over 25 years of experience in life sciences, previously serving at MilliporeSigma, where he oversaw strategy and business development. Interim CEO Jonathan Rothberg expressed confidence in Schneider's leadership to drive the company's ambitious plans for next-generation protein sequencing. Quantum-Si aims to revolutionize proteomics with its innovative semiconductor chip technology.

Tesseract Health has appointed Michael McConnell, MD, MSEE, as Head of Cardiovascular and Digital Health, strengthening its leadership under CEO Vicky Demas. Dr. McConnell brings expertise from Google Health and aims to guide the development of cardiovascular health products using Tesseract's non-invasive technology. The company is focused on democratizing health screening and aims to innovate ocular health diagnostics. Tesseract is part of 4Catalyzer, which includes companies like Butterfly Network (NYSE: BFLY), Quantum-Si (NASDAQ: QSI), and Hyperfine (NASDAQ: HYPR).